This page requires Adobe Flash Player.

Screening Those At Risk

In 2003, the American Thoracic Society (ATS) and the European Respiratory Society (ERS) issued Standards for the Diagnosis and Management of Individuals with Alpha-1 Antitrypsin Deficiency. In summary, the ATS recommends Alpha-1 testing for1:

  • All patients with COPD, emphysema, unexplained liver disease, or incompletely reversible asthma
  • Asymptomatic patients with persistent airflow obstructions and identifiable risk factors
  • Adults with necrotizing panniculitis

Download the complete ATS guidelines.

The American Thoracic Society (ATS) recommends Alpha-1 testing for1:

All Patients With

Asymptomatic Patients With

All Adult Patients With

COPD

Persistent airflow obstructions

Necrotizing panniculitis

Emphysema

Identifiable risk factors

 

Unexplained liver disease

Identifiable risk factors (cigarette smoking, occupational dust exposure, etc.)

 

Incompletely reversible asthma following aggressive bronchodilator treatment

 

 

Don't let Alpha-1 deficiency go undiagnosed.

To help you diagnose Alpha-1, CSL Behring has developed a number of educational and screening resources for use in your practice. Learn more about the steps you can take to improve the detection of Alpha-1 today.

References

1. American Thoracic Society/European Respiratory Society Task Force. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with Alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818-900.

 
Footer